DuPont Pioneer Gains Exclusive License for Genome-Editing Technology from Vilnius University

25-Jun-2015 - USA

DuPont Pioneer (DuPont) announced a technology license and research collaboration agreement with Vilnius University to further the technical and commercial utility of guided Cas9 genome editing technology. Under the agreement, DuPont receives an exclusive license to Vilnius University intellectual property for all commercial uses, including in agriculture. In addition, Vilnius University and DuPont have entered into a multi-year research collaboration to advance the development of the technology.

“Guided Cas9 is one of the most exciting recent breakthroughs in biology and, through our collaboration with Vilnius University, we’re positioning DuPont to be an early adopter of this promising new technology in agriculture,” said Neal Gutterson, vice president, Agricultural Biotechnology for DuPont Pioneer, the advanced plant genetics business of DuPont. “The superior properties of guided Cas9 assist our scientists to develop innovative and sustainable solutions for growers similar to those realized through marker-assisted plant breeding, but with even greater precision and accelerated development timelines.”

A team of scientists from the Vilnius University Institute of Biotechnology was one of the first groups to discover that the Cas9 protein could be repurposed to precisely edit targeted sections of an organism’s DNA to achieve a specific outcome.  In plants, this can include promoting drought tolerance and disease resistance for protecting plant health and increasing crop yields.

“We are pleased to have had our invention licensed by DuPont,” said Professor Virginijus Siksnys at the Institute of Biotechnology of Vilnius University. “The easy programmability of this customizable system brings unprecedented flexibility and versatility for precise genome editing. We have been and are continuing to collaborate with DuPont scientists to improve the technology further.”

Financial details of the agreement were not disclosed.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

European Medicines Agency advises on compassionate use of daclatasvir - Opinion concerns use in combination with sofosbuvir in patients with chronic hepatitis C in urgent need of therapy to prevent progression of liver disease

Galapagos initiates second Proof of Mechanism clinical study in GSK alliance - Phase I study measures effect on biomarker in healthy volunteers

Prosensa receives rare disease 'Company Award' from EURORDIS

Deutsche Gesellschaft für mukosale Immunologie und Mikrobiom (DGMIM) - Sindelfingen, Germany

AOP Orphan and Rigi Healthcare Start Rigi Orphan Inc., USA

Deutsche Hochdruckliga e.V. DHL® Deutsche Gesellschaft für Hypertonie und Prävention - Heidelberg, Germany

Traceless materials secures €36.6 Million Series A to build first industry plant for bio-circular alternative to plastic - Change-enabler for driving the green transformation of the industry

Traceless materials secures €36.6 Million Series A to build first industry plant for bio-circular alternative to plastic - Change-enabler for driving the green transformation of the industry

Researchers discover immunity genes that give frogs resistance to deadly fungus

Merck invests more than € 300 Million in new life science production site in South Korea - Site to supply products to customers for development and production of biologics

Merck invests more than € 300 Million in new life science production site in South Korea - Site to supply products to customers for development and production of biologics

Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients

Small Animal Imaging Crucial for Drug Development and Non-Invasive Identification of Diseases in Humans - Animal models are an efficient and cost-effective way to understand underlying mechanisms of several human conditions